BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus

BAFF, a member of the TNF superfamily, has been recognized as a good target for autoimmune diseases. Belimumab, an anti-BAFF monoclonal antibody, was approved by the FDA for use in treating systemic lupus erythematosus. However, the molecular basis of BAFF neutralization by belimumab remains unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Woori, Lee, Hyun Tae, Lim, Heejin, Lee, Sang Hyung, Son, Ji Young, Lee, Jee Un, Yoo, Ki-Young, Ryu, Seong Eon, Rhie, Jaejun, Lee, Ju Yeon, Heo, Yong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865148/
https://www.ncbi.nlm.nih.gov/pubmed/29572471
http://dx.doi.org/10.1038/s41467-018-03620-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865148/
https://www.ncbi.nlm.nih.gov/pubmed/29572471
http://dx.doi.org/10.1038/s41467-018-03620-2

Ejemplares similares